Zurich Cantonal Bank
BCRX icon

Zurich Cantonal Bank’s BioCryst Pharmaceuticals BCRX Stock Holding History

Zurich Cantonal Bank’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-57,351
Closed -$447K – 2678
2025
Q4 		$447K Buy
+57,351
New +$415K ﹤0.01% 1851

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Zurich Cantonal Bank's BCRX Position: Q2 2026 in Review

Zurich Cantonal Bank reduced its BioCryst Pharmaceuticals (BCRX) stake by 71% in Q2 2026, selling an estimated $1.35M and leaving 59,668 shares worth $597K. The position accounts for ﹤0.01% of the portfolio, ranked #1844.

Zurich Cantonal Bank first reported a position in BCRX in Q3 2015 and has held it in 43 quarters since. The position peaked at $1.99M in Q1 2026. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Zurich Cantonal Bank held 59,668 shares of BioCryst Pharmaceuticals worth $597K as of Q2 2026.
  • Zurich Cantonal Bank sold 149,235 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.35M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1844 holding.
  • Zurich Cantonal Bank first reported a position in BioCryst Pharmaceuticals in Q3 2015 and has held it in 43 quarters since.
  • Zurich Cantonal Bank's BioCryst Pharmaceuticals position peaked at $1.99M in Q1 2026.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.